Alligator Bioscience AB - Product Pipeline Review - Q1 2011

Global Markets Direct, March 2011, Pages: 31

Alligator Bioscience AB – Product Pipeline Review – Q1 2011

Summary

Global Market Direct’s pharmaceuticals report, “Alligator Bioscience AB - Product Pipeline Review - Q1 2011” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Alligator Bioscience AB - Brief company overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Alligator Bioscience AB human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Alligator Bioscience AB with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Alligator Bioscience AB’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Alligator Bioscience AB’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Alligator Bioscience AB in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Alligator Bioscience AB’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Alligator Bioscience AB.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Alligator Bioscience AB and identify potential opportunities in those areas.

List of Tables
List of Figures
Alligator Bioscience AB Snapshot
Alligator Bioscience AB Overview
Key Information
Key Facts
Alligator Bioscience AB – Research and Development Overview
Key Therapeutic Areas
Alligator Bioscience AB – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Alligator Bioscience AB – Pipeline Products Glance
Alligator Bioscience AB–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Discovery Products/Combination Treatment Modalities
Alligator Bioscience AB – Drug Profiles
ADC-1001
Product Description
Mechanism of Action
R&D Progress
ADC-1004
Product Description
Mechanism of Action
R&D Progress
ADC-1009
Product Description
Mechanism of Action
R&D Progress
ADC-1012
Product Description
Mechanism of Action
R&D Progress
ADC-1013
Product Description
Mechanism of Action
R&D Progress
ADC-1014
Product Description
Mechanism of Action
R&D Progress
Drug For Autoimmune Disorders
Product Description
Mechanism of Action
R&D Progress
Alligator Bioscience AB – Pipeline Analysis
Alligator Bioscience AB – Pipeline Products by Therapeutic Class
Alligator Bioscience AB - Pipeline Products By Target
Alligator Bioscience AB – Pipeline Products by Molecule Type
Alligator Bioscience AB – Locations And Subsidiaries
Head Office
Financial Deals Landscape
Alligator Bioscience AB, Deals Volume Summary, 2004 to YTD 2011
Alligator Bioscience AB, Deals Summary By Region, 2004 to YTD 2011
Alligator Bioscience AB, Deals Summary, 2004 to YTD 2011
Alligator Bioscience AB Detailed Deal Summary
Alligator Bioscience Enters Into Agreement With BioInvent
Alligator Bioscience Enters Into Research Agreement With PolyTherics
Alligator Bioscience Enters Into Strategic Collaboration With ImmuRx
Alligator Bioscience Enters Into Collaboration Agreement With An European Pharmaceutical Company
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Alligator Bioscience AB – Pipeline by Therapy Area and Indication, 2011
Alligator Bioscience AB – Pipeline by Stage of Development, 2011
Alligator Bioscience AB – Monotherapy Products in Pipeline, 2011
Alligator Bioscience AB - Pipeline By Therapeutic Class, 2011
Alligator Bioscience AB - Pipeline By Target, 2011
Alligator Bioscience AB – Pipeline By Molecule Type, 2011
Alligator Bioscience AB, Deals Summary, 2004 to YTD 2011
Alligator Bioscience AB, Deals Summary by Region, 2004 to YTD 2011
Alligator Bioscience AB, Deals Summary, 2004 to YTD 2011

List of Figures
Alligator Bioscience AB – Pipeline by Therapy Area and Indication, 2011
Alligator Bioscience AB – Pipeline by Stage of Development, 2011
Alligator Bioscience AB – Monotherapy Products in Pipeline, 2011
Alligator Bioscience AB – Pipeline By Therapeutic Class, 2011
Alligator Bioscience AB - Pipeline By Target, 2011
Alligator Bioscience AB – Pipeline By Molecule Type, 2011

Customers who bought this item also bought

• Top Five Global Software Companies: Performance, Strategies and Competitive Analysis
• ADC Telecommunications, Inc.
• Apple, Inc. - Strategies, Financial Outlook and Competitive Benchmark Analysis
• Hewlett-Packard Company - Strategies, Financial Outlook and Competitive Benchmark Analysis
• SunGard - Profile - US
• Sony Ericsson Mobile Communications AB
• Scientific Games Corporation - Company Analysis
• eBay - Strong Execution
• Insight into Samsung Electronics' Notebook PC Business Model
• Accenture - Profile - US